Probing hot spots at protein-ligand binding sites: A fragment-based approach using biophysical methods

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4992-5000

  Ciulli, Alessio ^a   Williams, Glyn ^b   Smith, Alison G ^a   Blundell, Tom L ^a   Abell, Chris ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KETOPANTOATE REDUCTASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG DESIGN; ENTHALPY; ENZYME ACTIVE SITE; ESCHERICHIA COLI; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; THERMODYNAMICS;

ALCOHOL OXIDOREDUCTASES; AMINO ACID SEQUENCE; BINDING SITES; BIOPHYSICS; CALORIMETRY; ESCHERICHIA COLI; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; NUCLEOTIDES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 33746885488     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060490r     Document Type: Article

References (50)

1. Kortemme, T.; Baker, D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14116-14121.
2. Delano, W. L. Unraveling hot spots in binding interfaces: Progress and challenges. Curr. Opin. Struct. Biol. 2002, 12, 14-20.
3. Arkin, M. R. and Wells, J. A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discovery 2004, 3, 301-317.
4. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 48, 2518-2525.
5. Huth, J. R.; Sun, C. H.; Sauer, D. R.; Hajduk, P. J. Utilization of NMR-derived fragment leads in drug design. Methods Enzymol. 2005, 549-571.
6. Rees, D. C.; Congreve, M. S.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.
7. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
8. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16, 741-753.
9. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
10. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C. A.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A. E.; Jhoti, H. Identification of novel p38 alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48, 414-426.
11. Ciulli, A.; Abell, C. Biophysical tools to monitor enzyme-ligand interactions of enzymes involved in vitamin biosynthesis. Biochem. Soc. Trans. 2005, 33, 767-771.
12. Blundell, T. L.; Jhoti, H.; Abell, C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discovery 2002, 1, 45-54.
13. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
14. Raimundo, B. C.; Oslob, J. D.; Braisted, A. C.; Hyde, J.; McDowell, R. S.; Randal, M.; Waal, N. D.; Wilkinson, J.; Yu, C. H.; Arkin, M. R. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: An approach for inhibiting protein-protein interactions. J. Med. Chem. 2004, 47, 3111-3130.
15. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 2003, 46, 4265-4272.
16. Frenkel, Y. V.; Clark, A. D.; Das, K.; Wang, Y. H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 2005, 48, 1974-1983.
17. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7, 522-527.
18. Lundqvist, T. The devil is still in the details -Driving early drug discovery forward with biophysical experimental methods. Curr. Opin. Drug Discovery Dev. 2005, 8, 513-519.
19. Webb, M. E.; Smith, A. G.; Abell, C. Biosynthesis of pantothenate. Nat. Prod. Rep. 2004, 21, 695-721.
20. Tahiliani, A. G.; Beinlich, C. J. Pantothenic acid in health and disease. Vitam. Horm. 1991, 46, 165-228.
21. Begley, T. P.; Kinsland, C.; Strauss, E. The biosynthesis of coenzyme A in bacteria. Vitam. Horm. 2001, 61, 157-171.
22. Murzin, A. G.; Brenner, S. E.; Hubbard, T.; Chothia, C. Scop - A structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 1995, 247, 536-540.
23. Zheng, R.; Blanchard, J. S. Kinetic and mechanistic analysis of the E. coli panE-encoded ketopantoate reductase. Biochemistry 2000, 39, 3708-3717.
24. Zheng, R.; Blanchard, J. S. Substrate specificity and kinetic isotope effect analysis of the Escherichia coli ketopantoate reductase. Biochemistry 2003, 42, 11289-11296.
25. Matak-Vinkovic, D.; Vinkovic, M.; Saldanha, S. A.; Ashurst, J. L.; von Delft, F.; Inoue, T.; Miguel, R. N.; Smith, A. G.; Blundell, T. L.; Abell, C. Crystal structure of Escherichia coli ketopantoate reductase at 1.7 Å resolution and insight into the enzyme mechanism. Biochemistry 2001, 40, 14493-14500.
26. + bound. Biochemistrv 2005, 44, 8930-8939.
27. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding. Structure 1998, 6, 839-848.
28. Turnbull, W. B.; Daranas, A. H. On the value of c: Can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 2003, 125, 14859-14866.
29. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18, 65-68.
30. Stockman, B. J.; Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc. 2002, 41, 187-231.
31. Zhang, Y. L.; Zhang, Z. Y. Low-affinity binding determined by titration calorimetry using a high-affinity coupling ligand: A thermodynamic study of ligand binding to protein tyrosine phosphatase 1B. Anal. Biochem. 1998, 267, 139-148.
32. Sigurskjold, B. W. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal. Biochem. 2000, 277, 260-266.
33. Lesk, A. M. NAD-binding domains of dehydrogenases. Curr. Opin. Struct. Biol. 1995, 5, 775-783.
34. Duax, W. L.; Pletnev, V.; Addlagatta, A.; Bruenn, J.; Weeks, C. M. Rational proteomics I. Fingerprint identification and cofactor specificity in the short-chain oxidoreductase (SCOR) enzyme family. Proteins: Struct., Funct., Genet. 2003, 53, 931-943.
35. Wierenga, R. K.; Terpstra, P.; Hol, W. G. Prediction of the occurrence of the ADP-binding beta alpha beta-fold in proteins, using an amino acid sequence fingerprint. J. Mol Biol. 1986, 187, 101-107.
36. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002.
37. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
38. Carr, R.; Congreve, M. S.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: Leads by design. Drug Discovery Today 2005, 10, 987-992.
39. Ward, W. H.; Holdgate, G. A. Isothermal titration calorimetry in drug discovery. Prog. Med. Chem. 2001, 38, 309-376.
40. Dunitz, J. D. Win some, lose some-Enthalpy-entropy compensation in weak intermolecular interactions. Chem. Biol. 1995, 2, 709-712.
41. Holdgate, G. A. and Ward, W. H. Measurements of binding thermodynamics in drug discovery. Drug Discovery Today 2005, 10, 1543-1550.
42. Nobeli, I.; Laskowski, R. A.; Valdar, W. S.; Thornton, J. M. On the molecular discrimination between adenine and guanine by proteins. Nucleic Acids Res. 2001, 29, 4294-4309.
43. Horecker, B. L.; Kornberg, A. The extinction coefficients of the reduced band of pyridine nucleotides. J. Biol. Chem. 1948, 175, 385-390.
44. Siegel, J. M.; Montgomery, G. A.; Bock, R. M. Ultraviolet absorption spectra of DPN and analogs of DPN. Arch. Biochem. Biophys. 1959, 82, 288-299.
45. Bock, R. M.; Ling, N. S.; Morell, S. A.; Lipton, S. H. Ultraviolet absorption spectra of adenosine-5′-triphosphate and related 5′-ribonucleotides. Arch. Biochem. Biophys. 1956, 62, 253-264.
46. Liu, R.; Visscher, J. A novel preparation of nicotinamide mononucleotide. Nucleosides Nucleotides 1994, 13, 1215-1216.
47. Leonidas, D. D.; Boix, E.; Prill, R.; Suzuki, M.; Turton, R.; Minson, K.; Swaminathan, G. J.; Youle, R. J.; Acharya, K. R. Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN)-High-resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors. J. Biol. Chem. 2001, 276, 15009-15017.
48. Morrison, J. F.; Stone, S. R. Mechanism of the reaction catalyzed by dihydrofolate reductase from Escherichia coli: pH and deuterium isotope effects with NADPH as the variable substrate. Biochemistry 1988, 27, 5499-5506.
49. Piotto, M.; Saudek, V.; Sklenar, V. Gradient-tailored excitation for single-quantum Nmr- spectroscopy of aqueous-solutions. J. Biomol. NMR 1992, 2, 661-665.
50. Wiseman, T.; Williston, S.; Brandts, J. F.; Lin, L. N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 1989, 179, 131-137.